Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 4/20 | 0.49 |
| ▸ | PAK3 | O75914 | 3/20 | 0.49 |
| ▸ | PAK2 | Q13177 | 3/20 | 0.49 |
| ▸ | PKN1 | Q16512 | 3/20 | 0.49 |
| ▸ | PAK4 | O96013 | 2/20 | 0.49 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.49 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CCND2 | P30279 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.41 |
| ▸ | WEE1 | P30291 | 6/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041889 | 0.82 | PAK3 (0.56) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL14681941 | 0.78 | CDK4 (0.49) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15041671 | 0.74 | PAK1 (0.37) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL13553798 | 0.73 | TNK2 (0.44) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15035969 | 0.73 | PAK3 (0.50) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15035987 | 0.72 | PAK1 (0.70) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15041469 | 0.72 | CDK4 (0.40) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15041449 | 0.72 | TNK2 (0.41) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL15030469 | 0.71 | PAK1 (0.82) | PAK1PAK3PAK2PKN1PAK4 | |
| SCHEMBL14693034 | 0.70 | CCNA2 (0.44) | PAK1PAK3PAK2PKN1PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | PAK1 6/4885PAK3 3/4885PAK2 1/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PAK1 4/4885PAK3 6/4885PAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.